Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients

NCT05237726 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Burns

Interventions

DRUG: Enoxaparin 40 mg q24 hours
DRUG: Enoxaparin 30 mg q12 hours
DRUG: Unfractionated heparin 5000 U q8 hours

Sponsor

King Abdullah International Medical Research Center